CCL22 and asthma: An obvious potential caveat of total CCR4 blockade as an asthma treatment is the potential for the impairment of regulatory T cell recruitment, since T-regulatory cells (Tregs) have been shown to express CCR4 and to migrate in vitro in response to both CCL17 and CCL22 (Iellem et al., 2001).